© 2024 HSP News Service, L.L.C.
In the phase Ib COSMIC-021 trial reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the combination of cabozantinib and atezolizumab produced durable responses in patients with advanced renal cell carcinoma (RCC). Study Details One hundred and two...
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses patient-reported outcomes for quality of life in the KEYNOTE-564 study, which previously met its primary endpoint of disease-free survival with adjuvant pembrolizumab vs placebo following surgery for renal cell carcinoma (Abstract 653O).
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk patients with clear cell renal cell...
On August 13, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg), a hypoxia-inducible factor inhibitor, for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or...
Recently, the U.S. Food and Drug Administration (FDA) accepted applications for agents aiming to treat non–small cell lung cancer (NSCLC), differentiated thyroid cancer, renal cell carcinoma (RCC), hypersensitive acute lymphoblastic leukemia (ALL), mucosal melanoma, and endometrial carcinoma....
On August 10, the U.S. Food and Drug Administration (FDA) approved the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). CLEAR Trial The efficacy of this combination was investigated in CLEAR...
On March 10, 2021, the VEGF tyrosine kinase inhibitor tivozanib was approved for treatment of adults with relapsed or refractory advanced renal cell carcinoma following at least two prior systemic therapies.1,2 Supporting Efficacy Data Approval was based on findings in the open-label, phase III...
In a population-based cohort study reported in JCO Oncology Practice, Stephanie B. Wheeler, PhD, and colleagues found a low rate of oral anticancer agent use within 12 months after detection of metastatic disease in patients with renal cell carcinoma. Study Details The study used a novel, North...
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
As reported in The Lancet Oncology by Chung-Han Lee, MD, and colleagues, findings in a cohort of the phase Ib/II Study 111/KEYNOTE-146 trial showed that the combination of lenvatinib and pembrolizumab produced high response rates among patients with metastatic clear cell renal cell carcinoma...
New research has uncovered substantial differences in the rates of childhood cancers when considering a single year of age rather than grouping several years together. The study, published by Marcotte et al in the journal Cancer, also found that minority children seem to have different risks than...
The pace of clinical research in metastatic renal cell carcinoma is faster than ever. Over the past 5 years, we have seen data from six phase III clinical trials evaluating combination strategies with checkpoint inhibitors. The era began with data from CheckMate 214, evaluating nivolumab with...
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract 4502).
Brian I. Rini, MD, of Vanderbilt University, discusses findings from KEYNOTE-426, the longest follow-up of a checkpoint inhibitor (pembrolizumab) combined with a VEGF/VEGFR inhibitor (axitinib) for first-line clear cell renal cell carcinoma. The trial results continue to support this combination as a standard of care for patients with previously untreated disease (Abstract 4500).
A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...
Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results from KEYNOTE-564, which evaluated the safety and efficacy of pembrolizumab in the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy for intermediate-high or high-risk disease or no evidence of disease (Abstract LBA5).
In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...
The American Urological Association (AUA) announced amendments to its clinical guideline on Renal Masses and Localized Renal Cancer, originally published in 2013 and updated in 2017, based on an additional literature search conducted through October 2020. One in four renal masses are benign;...
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...
Recently, the U.S. Food and Drug Administration (FDA) has granted Priority Review to the combination of pembrolizumab and lenvatinib for the treatment of both advanced renal cell carcinoma (RCC) and endometrial carcinoma. The FDA also granted Priority Review to ivosidenib for the treatment of...
Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...
Landmark changes in the treatment of genitourinary cancers have occurred over the past year, as summarized in this year’s Genitourinary Oncology Almanac from The ASCO Post. Starting with our area of focus, metastatic renal cell carcinoma, the saga continues with two more positive phase III trials...
As reported in The New England Journal of Medicine by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center (MSK), and colleagues, the phase III CLEAR trial has shown prolonged progression-free survival with lenvatinib/pembrolizumab and with lenvatinib/everolimus vs sunitinib and...
A report published by Kotecha et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests that baseline brain imaging should be considered in most patients with metastatic renal cell carcinoma (RCC). Researchers found incidental brain metastases occur in a clinically significant...
Samra Turajlic, MBBS, PhD, of The Francis Crick Institute, discusses our limited understanding of metastases in terms of the timing of dissemination, the many metastatic phenotypes and varieties of seeding, as well as how the spread of cancer evades the immune system and resists treatment. Expanding this knowledge base is critical to better managing malignant disease.
Brian I. Rini, MD, of Vanderbilt University, discusses the IMmotion151 trial results on overall survival and the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (Abstract CT188).
Invited discussant David A. Braun, MD, PhD, of Dana-Farber Cancer Institute, Boston, said there are a couple of established pillars of systemic therapy for metastatic renal cell carcinoma (RCC). “An immune checkpoint inhibitor is a strong pillar, a [vascular endothelial growth factor tyrosine...
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Xin Gao, MD, a medical oncologist at Mass General Hospital and Instructor at Harvard Medical School, said these were important findings. “Analyses of patient-reported outcomes pertaining to health-related quality-of-life measures from CheckMate 9ER showed significantly improved quality-of-life...
Results of the CheckMate 9ER phase III trial showed significantly improved patient-reported outcomes in quality of life for first-line treatment with nivolumab plus cabozantinib compared with sunitinib for patients with advanced renal cell carcinoma.1 These findings are in line with the previously...
The treatment paradigm for patients with metastatic renal cell carcinoma has undergone a dramatic shift over the past few years, improving outcomes for many patients but leaving many unanswered questions as to how to optimally choose the best treatment for an individual patient. The changes are...
As reported in two articles in the Journal of Clinical Oncology by David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and colleagues, the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment in cohorts of patients with...
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the several hereditary renal cell cancer syndromes, the importance of surveillance for both renal and nonrenal manifestations, and the treatment options available.
On January 22, 2021, the U.S. Food and Drug Administration approved the combination of nivolumab and cabozantinib as first-line treatment for patients with advanced renal cell carcinoma.1-3 Supporting Efficacy Data Approval was based on the findings of the phase III, open-label CheckMate 9ER trial...
Cabozantinib achieved a statistically significant and clinically meaningful extension in progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma, a relatively uncommon type of renal cell carcinoma, according to the randomized phase II SWOG 1500...
The combination of lenvatinib plus pembrolizumab was superior to sunitinib for progression-free and overall survival as well as other key endpoints in patients with advanced clear cell renal cell carcinoma (RCC), according to results of the phase III CLEAR trial presented at the 2021 Genitourinary ...
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to the HIF-2α inhibitor belzutifan for the treatment of patients with von Hippel-Lindau (VHL) disease–associated renal cell carcinoma. The agency also granted Fast Track designation to poziotinib for the treatment of...
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and overall survival vs sunitinib in first-line treatment of patients with...
In a study reported in a research letter in JAMA Oncology, Lalani et al found that higher body mass index (BMI) was associated with better overall survival among patients with metastatic renal cell carcinoma receiving anti–PD-1/PD-L1–based immune checkpoint inhibitor treatment. No association of...
On March 10, the U.S. Food and Drug Administration (FDA) approved tivozanib (Fotivda), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. TIVO-3 Efficacy was evaluated in TIVO-3 (ClinicalTrials.gov...
In the phase II SWOG 1500 study reported in The Lancet, Pal et al found that among three comparator MET kinase inhibitors, cabozantinib prolonged progression-free survival vs sunitinib in metastatic papillary renal cell carcinoma. Study Details In the open-label trial, 147 eligible patients from...
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
As reported in the Journal of Clinical Oncology by McDermott et al, findings in a cohort of the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment for advanced non–clear cell renal cell carcinoma. In a separate cohort of the study,...
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on renal cell carcinoma and offers her views on the latest trends and findings (Abstracts 269, 308, 270, 313).
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of treatment (Abstract 327).
Sumanta K. Pal, MD, of City of Hope, discusses findings of the TIVO-3 study, which showed that the tyrosine kinase inhibitor tivozanib improved progression-free survival vs sorafenib in patients whose advanced renal cell carcinoma progressed after multiple lines of therapy (Abstract 278).
Sumanta K. Pal, MD, of City of Hope, discusses phase II results from the SWOG 1500 study, which showed that compared with crizotinib and savolitinib, cabozantinib was the only agent that prolonged progression-free survival vs sunitinib in patients with metastatic papillary renal cell carcinoma (Abstract 270).
A spirited discussion ensued when we asked Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, to compare notes on how they treat bladder, prostate, and kidney cancers.